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Safety of single vs multiple food oral immunotherapy in a private practice setting Allyson T. Tevrizian, MD; Allergy and Asthma Group of the Bay Area, Pleasanton, CA; Allergy and Asthma Medical Group, Walnut Creek, CA. RATIONALE: Oral immunotherapy (OIT) with single and multiple foods is increasingly used for treatment in community settings. Ascertaining the safety profile of such therapy is paramount. METHODS: A retrospective chart review of 121 patients completing single or multiple food OIT was conducted. Data on number of treated foods, concomitant omalizumab administration, and adverse reactions was analyzed. RESULTS: Sixty-three of 69 enrolled multiple food OIT patients and 51 of 52 enrolled single food OIT patients successfully completed OIT buildup. Twenty-four of the multiple food and 9 of the single food OIT patients used concomitant omalizumab. In the multiple food OIT group, 29(42%) patients experienced cutaneous symptoms, 29(42%) respiratory, 53(76%) gastrointestinal, and 1(1%) cardiovascular during treatment. Twenty-seven(39%) patients had reactions requiring dose adjustment. Five of 24 omalizumab users versus 22 of 45 non-omalizumab users had reactions requiring dose adjustment(p50.02). Epinephrine-requiring reactions occurred in 8(12%) of the multiple food group, 3 who used omalizumab. In the single food OIT group, 23(44%) patients experienced cutaneous symptoms, 22(42%) respiratory, 40(76%) gastrointestinal, and 1(2%) cardiovascular during treatment. Twenty (30%) patients had reactions requiring dose adjustment. One of 9 omalizumab users versus 19 of 20 nonomalizumab users had reactions requiring dose adjustment(p50.06). In the USA, the diagnosis of tree nut and seed allergy appears to have increased in recent years. An association between tree nut and sesame allergy has been observed, and we noticed a particular association between cashew and sesame allergy. We sought to investigate this further. METHODS: We reviewed electronic medical records for office visits between July 1-20, 2016 at our pediatric allergy practice. Patients with evidence of cashew sensitization, defined as skin prick test (SPT) wheal 3 mm greater than the negative control or cashew-specific serum IgE >0.35 kU A /L (ssIgE), who were avoiding cashew were identified. Demographic, clinical, and laboratory data were compiled. RESULTS: We reviewed 214 visits and identified 100 patients with cashew sensitization including 57% males, 43% females, median age 7.6 years (range: 8 months-20 years). A history of a convincing allergic reaction to cashew was documented in 21 patients (21%). The median cashew-ssIgE was 7.8 kU A /L (Immunocap, range: <0.35->100 kU A /L), and the median SPT wheal diameter was 8 mm (range: 0-20 mm). Fortyone (41%) of cashew-sensitized patients were avoiding sesame, and of those, 16 (39%) patients had a history of a convincing allergic reaction to sesame. Three patients (3/21, 14.3%) had convincing allergic reactions to both cashew and sesame. The median sesame-ssIgE was 22.1 kU A /L (range: 0.38->100 kU A /L); the median SPT was 5 mm (range: 0-23 mm). Patients with higher cashew-ssIgE were more likely to avoid sesame (P5.02). CONCLUSIONS: Cashew allergy is common in our practice, and there is a high rate of allergic co-sensitization between cashew and sesame.
